数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Michael Friedman Director 73 19.78万美元 未持股 2017-03-06
Joseph C. Papa Director 61 19.78万美元 未持股 2017-03-06
Robin Freestone Director 58 9.13万美元 未持股 2017-03-06
Erik Engstrom Director 53 9.13万美元 未持股 2017-03-06
Ian E. Barlow Director 65 11.52万美元 未持股 2017-03-06
Brian Larcombe Director 63 11.52万美元 未持股 2017-03-06
Roberto Quarta Chairman 67 52.66万美元 未持股 2017-03-06
Vinita Bali Director 61 10.70万美元 未持股 2017-03-06
Baroness Bottomley Director 68 9.13万美元 未持股 2017-03-06

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Graham Baker Chief Financial Officer 48 未披露 未持股 2017-03-06
Susan Swabey Company Secretary 55 未披露 未持股 2017-03-06
Glenn Warner President, Us 54 未披露 未持股 2017-03-06
Elga Lohler Chief Human Resources Officer 49 未披露 未持股 2017-03-06
Matthew Stober President, Global Operations 49 未披露 未持股 2017-03-06
Brad Cannon President, Europe And Canada 49 未披露 未持股 2017-03-06
Vasant Padmanabhan President Of Research & Development 50 未披露 未持股 2017-03-06
Olivier Bohuon Chief Executive Officer 58 597.31万美元 未持股 2017-03-06
Michael Frazzette Chief Commercial Officer 55 未披露 未持股 2017-03-06
Jack Campo Chief Legal Officer 62 未披露 未持股 2017-03-06
Olivier Bohuon Chief Executive Officer 58 未披露 未持股 2017-03-06
Cyrille Petit Chief Corporate Development Officer And President, Global Business Services 46 未披露 未持股 2017-03-06
Rodrigo Bianchi President, Asia Pacific And Emerging Markets 57 未披露 未持股 2017-03-06

董事简历

中英对照 |  中文 |  英文
Michael Friedman

Michael Friedman,2003年12月开始就是董事。2003年就是希望城国家医学中心(the City of Hope National Medical Center)的首席执行官和总裁。2001年9月到2003年4月,他是法玛西亚公司(Pharmacia Corporation)研究和发展部,医疗和公共政策部的高级副总裁。1999年7月到2001年9月,他是赛尔公司(Searle 孟山都公司Monsanto Company的子公司)的高级副总裁。1995年到1999年6月,他是食品和药物管理局(Food and Drug Administration)营运部的副税务长。1997年到1998年,他是代理专员和副专员。他获得路易斯安那新奥尔良的杜兰大学(Tulane University)的文学学士学位,是优等生。他获得来自德克萨斯大学(the University of Texas)西南医学院的医学博士学位。


Michael Friedman, M.D. has served as one of the company's directors since February 2011 and a member of the Nominating Committee since April 2011. Dr. Friedman is the emeritus Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as Director of the organization’s Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director’s Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman has served as Deputy Commissioner for the U.S. Food and Drug Administration FDA, later serving as Acting Commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004 Dr. Friedman has served on the Independent Citizens’ Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of California’s stem cell research effort. Dr. Friedman is a member of the Board of Directors of MannKind Corporation, Smith & Nephew plc. and Intuitive Surgical, Inc. He also serves on the Board of Trustees for Tulane University.
Michael Friedman,2003年12月开始就是董事。2003年就是希望城国家医学中心(the City of Hope National Medical Center)的首席执行官和总裁。2001年9月到2003年4月,他是法玛西亚公司(Pharmacia Corporation)研究和发展部,医疗和公共政策部的高级副总裁。1999年7月到2001年9月,他是赛尔公司(Searle 孟山都公司Monsanto Company的子公司)的高级副总裁。1995年到1999年6月,他是食品和药物管理局(Food and Drug Administration)营运部的副税务长。1997年到1998年,他是代理专员和副专员。他获得路易斯安那新奥尔良的杜兰大学(Tulane University)的文学学士学位,是优等生。他获得来自德克萨斯大学(the University of Texas)西南医学院的医学博士学位。
Michael Friedman, M.D. has served as one of the company's directors since February 2011 and a member of the Nominating Committee since April 2011. Dr. Friedman is the emeritus Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as Director of the organization’s Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director’s Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman has served as Deputy Commissioner for the U.S. Food and Drug Administration FDA, later serving as Acting Commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004 Dr. Friedman has served on the Independent Citizens’ Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of California’s stem cell research effort. Dr. Friedman is a member of the Board of Directors of MannKind Corporation, Smith & Nephew plc. and Intuitive Surgical, Inc. He also serves on the Board of Trustees for Tulane University.
Joseph C. Papa

Joseph C. Papa,他是Remuneration Committee的独立非执行董事长。2008年8月他被任命为非执行董事。2011年4月他被任命为Remuneration Committee主席。他是道德与合规和审计委员会成员。他有超过30年的许多美国和瑞士公司制药行业工作的经验。他目前是Perrigo Company plc(美国最大的柜台制药公司之一)的主席和首席执行官。他曾担任Novartis International AG、Cardinal Health, Inc和Pharmacia Corporation的高级职务。


Joseph C. Papa has served as our Chief Executive Officer of the Company and Chairman of the Board of Directors since January 2022. Mr. Papa has also served as Chairman of the Board of Director and Chief Executive Officer of BHC since May 2016. Mr. Papa has more than 35 years of experience in the pharmaceutical, healthcare and specialty pharmaceutical industries, including 20 years of branded prescription drug experience. He served as the Chief Executive Officer of Perrigo Company plc "Perrigo" from 2006 to April 2016 where he also served as Chairman from 2007 to April 2016. Prior to joining Perrigo, Mr. Papa served from 2004 to 2006 as Chairman and Chief Executive Officer of the Pharmaceutical and Technologies Services segment of Cardinal Health, Inc. From 2001 to 2004 he served as President and Chief Operating Officer of Watson Pharmaceuticals, Inc. ("Watson"). Prior to joining Watson, Mr. Papa held management positions at DuPont Pharmaceuticals, Pharmacia/Searle and Novartis AG. Mr. Papa holds a BS in pharmacy from the University of Connecticut and an MBA from Northwestern University's Kellogg Graduate School of Management. Mr. Papa joined the board of directors of Prometheus Biosciences, Inc., a privately held biopharmaceutical company, in August 2020 and previously served as a director of Smith & Nephew plc, a publicly traded medical device company, from 2008 to April 2018.
Joseph C. Papa,他是Remuneration Committee的独立非执行董事长。2008年8月他被任命为非执行董事。2011年4月他被任命为Remuneration Committee主席。他是道德与合规和审计委员会成员。他有超过30年的许多美国和瑞士公司制药行业工作的经验。他目前是Perrigo Company plc(美国最大的柜台制药公司之一)的主席和首席执行官。他曾担任Novartis International AG、Cardinal Health, Inc和Pharmacia Corporation的高级职务。
Joseph C. Papa has served as our Chief Executive Officer of the Company and Chairman of the Board of Directors since January 2022. Mr. Papa has also served as Chairman of the Board of Director and Chief Executive Officer of BHC since May 2016. Mr. Papa has more than 35 years of experience in the pharmaceutical, healthcare and specialty pharmaceutical industries, including 20 years of branded prescription drug experience. He served as the Chief Executive Officer of Perrigo Company plc "Perrigo" from 2006 to April 2016 where he also served as Chairman from 2007 to April 2016. Prior to joining Perrigo, Mr. Papa served from 2004 to 2006 as Chairman and Chief Executive Officer of the Pharmaceutical and Technologies Services segment of Cardinal Health, Inc. From 2001 to 2004 he served as President and Chief Operating Officer of Watson Pharmaceuticals, Inc. ("Watson"). Prior to joining Watson, Mr. Papa held management positions at DuPont Pharmaceuticals, Pharmacia/Searle and Novartis AG. Mr. Papa holds a BS in pharmacy from the University of Connecticut and an MBA from Northwestern University's Kellogg Graduate School of Management. Mr. Papa joined the board of directors of Prometheus Biosciences, Inc., a privately held biopharmaceutical company, in August 2020 and previously served as a director of Smith & Nephew plc, a publicly traded medical device company, from 2008 to April 2018.
Robin Freestone

Robin Freestone,2014年加入Pearson担任副首席财务官,2006年6月成为首席财务官。Robin在Touche Ross(现称Deloitte)一个合格的特许会计师,他目前是eChem Limited的非执行主管和创始股东。Robin任职于the ICAE 财务报告委员会的咨询团队,并担任The Hundred Group of Finance Directors的主席。


Robin Freestone,joined Capri Holdings Limited Board in November 2016. He was Chief Financial Officer of Pearson Plc, from 2006 through August 2015, having previously served as Deputy Chief Financial Officer since 2004. Prior to that, he held a number of senior financial positions at Amersham plc from 2000 to 2004, Henkel Chemicals UK Ltd from 1995 to 2000 and ICI/Zeneca Agrochemicals Ltd (now Syngenta) from 1985 to 1995. He began his financial and accounting career at Touche Ross (now Deloitte). Mr. Freestone also serves as a non-executive director of Aston Martin Lagonda and as Chairman of the Board of moneysupermarket.com.
Robin Freestone,2014年加入Pearson担任副首席财务官,2006年6月成为首席财务官。Robin在Touche Ross(现称Deloitte)一个合格的特许会计师,他目前是eChem Limited的非执行主管和创始股东。Robin任职于the ICAE 财务报告委员会的咨询团队,并担任The Hundred Group of Finance Directors的主席。
Robin Freestone,joined Capri Holdings Limited Board in November 2016. He was Chief Financial Officer of Pearson Plc, from 2006 through August 2015, having previously served as Deputy Chief Financial Officer since 2004. Prior to that, he held a number of senior financial positions at Amersham plc from 2000 to 2004, Henkel Chemicals UK Ltd from 1995 to 2000 and ICI/Zeneca Agrochemicals Ltd (now Syngenta) from 1985 to 1995. He began his financial and accounting career at Touche Ross (now Deloitte). Mr. Freestone also serves as a non-executive director of Aston Martin Lagonda and as Chairman of the Board of moneysupermarket.com.
Erik Engstrom

Erik Engstrom,自2009年担任首席执行官,他在2004年加入Reed Elsevier担任首席执行官,加入Reed Elsevier之前,他是General Atlantic Partners。的合作伙伴,之前,他是Random House公司的总裁兼首席运营官,在与Random House合并之前,他是Bantam Doubleday Dell北美区域的总裁兼首席执行官。他开始他的职业生涯作为一个麦肯锡顾问。担任Eniro AB和Svenska Cellulosa Aktiebolaget SCA的非执行董事。他拥有从斯德哥尔摩经济学院的学士学位信,获得斯德哥尔摩皇家理工学院的理学硕士学位,并作为富布赖特学者获得了哈佛商学院的MBA学位。


Erik Engstrom, Chief Executive Officer of RELX Group since November 2009. Joined the Group as Chief Executive Officer of Elsevier in 2004. Non-Executive Director of Smith & Nephew plc. Prior to joining the Group was a partner at General Atlantic Partners. Before that was President and Chief Operating Officer of Random House Inc and President and Chief Executive Officer of Bantam Doubleday Dell, North America. Began his career as a consultant with McKinsey. Served as a Non-Executive Director of Eniro AB and Svenska Cellulosa Aktiebolaget SCA. Holds a BSc from Stockholm School of Economics, an MSc from the Royal Institute of Technology in Stockholm, and gained an MBA from Harvard Business School as a Fulbright Scholar.
Erik Engstrom,自2009年担任首席执行官,他在2004年加入Reed Elsevier担任首席执行官,加入Reed Elsevier之前,他是General Atlantic Partners。的合作伙伴,之前,他是Random House公司的总裁兼首席运营官,在与Random House合并之前,他是Bantam Doubleday Dell北美区域的总裁兼首席执行官。他开始他的职业生涯作为一个麦肯锡顾问。担任Eniro AB和Svenska Cellulosa Aktiebolaget SCA的非执行董事。他拥有从斯德哥尔摩经济学院的学士学位信,获得斯德哥尔摩皇家理工学院的理学硕士学位,并作为富布赖特学者获得了哈佛商学院的MBA学位。
Erik Engstrom, Chief Executive Officer of RELX Group since November 2009. Joined the Group as Chief Executive Officer of Elsevier in 2004. Non-Executive Director of Smith & Nephew plc. Prior to joining the Group was a partner at General Atlantic Partners. Before that was President and Chief Operating Officer of Random House Inc and President and Chief Executive Officer of Bantam Doubleday Dell, North America. Began his career as a consultant with McKinsey. Served as a Non-Executive Director of Eniro AB and Svenska Cellulosa Aktiebolaget SCA. Holds a BSc from Stockholm School of Economics, an MSc from the Royal Institute of Technology in Stockholm, and gained an MBA from Harvard Business School as a Fulbright Scholar.
Ian E. Barlow

Ian E. Barlow,他是审计委员会主席和独立非执行董事。2010年3月他被任命为非执行董事。2010年5月他被任命为审计委员会主席。他是会计师并有在英国和国际上丰富的财务经验。在2008年他退休之前,他是毕马威会计事务所(KPMG)的合伙人和后来的伦敦高级合伙人。在毕马威会计事务所(KPMG)的事业,他曾是英国税务和法律业务负责人。他担任在北美,欧洲和亚洲运营的许多大型国际组织的领导合伙人。


Ian E. Barlow is a Chartered Accountant with considerable financial experience both internationally and in the UK. He was a Partner at KPMG, latterly Senior Partner, London, until 2008. At KPMG, he was Head of UK tax and legal operations. He has also been Chairman of WSP Group plc, and currently is NED and Chairman of the Audit Committees of The Brunner Investment Trust PLC, Foxtons Group plc and Urban&Civic plc.
Ian E. Barlow,他是审计委员会主席和独立非执行董事。2010年3月他被任命为非执行董事。2010年5月他被任命为审计委员会主席。他是会计师并有在英国和国际上丰富的财务经验。在2008年他退休之前,他是毕马威会计事务所(KPMG)的合伙人和后来的伦敦高级合伙人。在毕马威会计事务所(KPMG)的事业,他曾是英国税务和法律业务负责人。他担任在北美,欧洲和亚洲运营的许多大型国际组织的领导合伙人。
Ian E. Barlow is a Chartered Accountant with considerable financial experience both internationally and in the UK. He was a Partner at KPMG, latterly Senior Partner, London, until 2008. At KPMG, he was Head of UK tax and legal operations. He has also been Chairman of WSP Group plc, and currently is NED and Chairman of the Audit Committees of The Brunner Investment Trust PLC, Foxtons Group plc and Urban&Civic plc.
Brian Larcombe

Brian Larcombe,他是独立非执行董事。2002年3月他被任命为非执行董事。他是提名和治理、审计和薪酬委员会的成员。在2014年4月10日的年度股东大会,他成为高级独立董事。他在3i Group的私募股权公司度过他的职业生涯。在领导英国投资业务几年之后,他成为财务董事。然后在公司上市后,他成为其首席执行官。他在城市里被众人所熟知并担任一些非执行董事职务。


Brian Larcombe graduated with a Bachelor’s of Commerce degree from University of Birmingham. He spent most of his career in private equity with 3i Group plc, becoming Finance Director and then Chief Executive of the Group following its flotation. He has held a number of Non-Executive Directorships and is currently Non-Executive Director of Kodak Alaris Holdings Limited and Cape plc.
Brian Larcombe,他是独立非执行董事。2002年3月他被任命为非执行董事。他是提名和治理、审计和薪酬委员会的成员。在2014年4月10日的年度股东大会,他成为高级独立董事。他在3i Group的私募股权公司度过他的职业生涯。在领导英国投资业务几年之后,他成为财务董事。然后在公司上市后,他成为其首席执行官。他在城市里被众人所熟知并担任一些非执行董事职务。
Brian Larcombe graduated with a Bachelor’s of Commerce degree from University of Birmingham. He spent most of his career in private equity with 3i Group plc, becoming Finance Director and then Chief Executive of the Group following its flotation. He has held a number of Non-Executive Directorships and is currently Non-Executive Director of Kodak Alaris Holdings Limited and Cape plc.
Roberto Quarta

Roberto Quarta,他于2001年加入Clayton, Dubilier & Rice公司(私人股本公司),担任运营合伙人,并于2009年被任命为欧洲主席。他曾担任BBA Group公司(跨国航空服务和材料技术公司)的首席执行官(从1993年到2001年),随后担任主席(2001年至2007年)。此前,他曾任职BTR公司(全球多元化的工业集团)17年,担任多种高级管理职位。他目前担任Rexel公司(全球领先的工业、住宅和商业部门电气分销商)的监事会主席。他任职于IMI公司(一个国际工程集团)的董事会,并于2011年11月1日成为非执行主席。他曾担任BAE Systems公司(全球国防安全和航空公司)、Azure Dynamics Corporation(混合动力电动汽车、控制和动力系统的制造商)、Equant NV(全球局域网通讯供应商)、PowerGen公司(大型英国能源供应商)的董事。


Roberto Quarta was appointed as a Director on 1 January 2015 and became Chairman on 9 June 2015. Roberto has extensive and diverse experience in corporate governance and global commerce. He is Partner and Chairman of Clayton, Dubilier & Rice Europe, a private equity firm. Roberto has an in-depth understanding of differing global governance requirements having served on the boards of a number of UK and international companies, including as Chairman of BBA Group plc, IMI plc and Rexel SA and as Non-Executive Director of BAE Systems plc, Equant NV and Foster Wheeler AG.
Roberto Quarta,他于2001年加入Clayton, Dubilier & Rice公司(私人股本公司),担任运营合伙人,并于2009年被任命为欧洲主席。他曾担任BBA Group公司(跨国航空服务和材料技术公司)的首席执行官(从1993年到2001年),随后担任主席(2001年至2007年)。此前,他曾任职BTR公司(全球多元化的工业集团)17年,担任多种高级管理职位。他目前担任Rexel公司(全球领先的工业、住宅和商业部门电气分销商)的监事会主席。他任职于IMI公司(一个国际工程集团)的董事会,并于2011年11月1日成为非执行主席。他曾担任BAE Systems公司(全球国防安全和航空公司)、Azure Dynamics Corporation(混合动力电动汽车、控制和动力系统的制造商)、Equant NV(全球局域网通讯供应商)、PowerGen公司(大型英国能源供应商)的董事。
Roberto Quarta was appointed as a Director on 1 January 2015 and became Chairman on 9 June 2015. Roberto has extensive and diverse experience in corporate governance and global commerce. He is Partner and Chairman of Clayton, Dubilier & Rice Europe, a private equity firm. Roberto has an in-depth understanding of differing global governance requirements having served on the boards of a number of UK and international companies, including as Chairman of BBA Group plc, IMI plc and Rexel SA and as Non-Executive Director of BAE Systems plc, Equant NV and Foster Wheeler AG.
Vinita Bali

Vinita Bali,2005年起,担任Britannia Industries的总经理、首席执行官,这是印度的优质食品上市公司。她也是Titan Industries、Piramal Glass、The Wadia Group旗下几个公司、GAIN Global Alliance for Improved Nutrition的非执行董事。职业生涯之初,她任职于印度的Tata Group,后来依次任职于Cadbury的英国、尼日利亚和南非地区。1994年以来,她在美国和拉丁美洲的The Coca-Cola Company,担任过一些营销和综合管理方面的高级职务,在2001年成为企业战略总监;后来,2003年加入Zyman Group,担任美国的商业策略业务部总监。她在The Jamnalal Bajaj Institute of Management Studies, University of Bombay获得工商管理硕士学位,在University of Delhi获得经济学士学位。


Vinita Bali,Britannia Industries, an international food products company based in India and listed on the National Stock Exchange and Bombay Stock Exchange in India,Chief Executive Officer and Managing Director,Public company CEO experience directing and shaping strategy for an international food products company.The Zyman Group, a marketing and communications strategy firm,Managing Principal and Head of Business Strategy Practice, USA.The Coca-Cola Company (KO), a multinational beverage company Officer, Vice President and Head, Corporate Strategy (2001 – 2003),President, Andean Division (1999 – 2000),Vice President, Marketing for Latin America (1997 – 1998),Worldwide Marketing Director (1994 – 1997),Executive-level business, operational and marketing leadership roles, based in the United States and Chile, for key divisions around the globe for a then Fortune 100, NYSE listed company.Cadbury Schweppes plc, a multinational confectionery company,Senior marketing roles across a number of geographies, including South Africa, Nigeria, India and the U.K.Senior business, operational and marketing leadership roles across a number of geographies for a leading multinational confectionery company.Current public company boards Bajaj Auto Ltd. (BAJAJ-AUTO), a multinational automotive manufacturing company listed on the National Stock Exchange ("NSE") in India ,SATS Ltd. (S58), a leading provider of food solutions and gateway services and listed on the Singapore Stock Exchange,Syngene International Ltd., a research and manufacturing company listed on the NSE and Bombay Stock Exchange ("BSE") in India.Past director positions CRISIL Ltd., a global analytical company providing ratings, research and risk and policy advisory services listed on the NSE and BSE Bunge Ltd. (BG), an agribusiness and food company Smith & Nephew Plc (SNN), a global portfolio medical technology business.
Vinita Bali,2005年起,担任Britannia Industries的总经理、首席执行官,这是印度的优质食品上市公司。她也是Titan Industries、Piramal Glass、The Wadia Group旗下几个公司、GAIN Global Alliance for Improved Nutrition的非执行董事。职业生涯之初,她任职于印度的Tata Group,后来依次任职于Cadbury的英国、尼日利亚和南非地区。1994年以来,她在美国和拉丁美洲的The Coca-Cola Company,担任过一些营销和综合管理方面的高级职务,在2001年成为企业战略总监;后来,2003年加入Zyman Group,担任美国的商业策略业务部总监。她在The Jamnalal Bajaj Institute of Management Studies, University of Bombay获得工商管理硕士学位,在University of Delhi获得经济学士学位。
Vinita Bali,Britannia Industries, an international food products company based in India and listed on the National Stock Exchange and Bombay Stock Exchange in India,Chief Executive Officer and Managing Director,Public company CEO experience directing and shaping strategy for an international food products company.The Zyman Group, a marketing and communications strategy firm,Managing Principal and Head of Business Strategy Practice, USA.The Coca-Cola Company (KO), a multinational beverage company Officer, Vice President and Head, Corporate Strategy (2001 – 2003),President, Andean Division (1999 – 2000),Vice President, Marketing for Latin America (1997 – 1998),Worldwide Marketing Director (1994 – 1997),Executive-level business, operational and marketing leadership roles, based in the United States and Chile, for key divisions around the globe for a then Fortune 100, NYSE listed company.Cadbury Schweppes plc, a multinational confectionery company,Senior marketing roles across a number of geographies, including South Africa, Nigeria, India and the U.K.Senior business, operational and marketing leadership roles across a number of geographies for a leading multinational confectionery company.Current public company boards Bajaj Auto Ltd. (BAJAJ-AUTO), a multinational automotive manufacturing company listed on the National Stock Exchange ("NSE") in India ,SATS Ltd. (S58), a leading provider of food solutions and gateway services and listed on the Singapore Stock Exchange,Syngene International Ltd., a research and manufacturing company listed on the NSE and Bombay Stock Exchange ("BSE") in India.Past director positions CRISIL Ltd., a global analytical company providing ratings, research and risk and policy advisory services listed on the NSE and BSE Bunge Ltd. (BG), an agribusiness and food company Smith & Nephew Plc (SNN), a global portfolio medical technology business.
Baroness Bottomley

Baroness Bottomley,她是非执行董事。2012年4月她被任命为非执行董事。她是the Remuneration Committee成员。她有丰富的经验和对医疗保健深刻的了解。2005年她被授予终身贵族并成为下院议员(1984年到2005年)。她相继地担任卫生大臣和民族遗产秘书。她担任许多公共和私人医疗保健部门的职务。


Baroness Bottomley gained her MSc in Social Administration from the London School of Economics following her first degree. She was appointed a Life Peer in 2005 following her career as a Member of Parliament between 1984 and 2005. She served successively as Secretary of State for Health and then Culture, Media and Sport. Virginia was formerly a director of Bupa and AkzoNobel NV. She is currently a director of International Resources Group Limited, member of the International Advisory Council of Chugai Pharmaceutical Co, Chancellor of University of Hull and Sheriff of Hull and Trustee of The Economist Newspaper. She is the Chair of Board & CEO Practice at Odgers Berndtson.
Baroness Bottomley,她是非执行董事。2012年4月她被任命为非执行董事。她是the Remuneration Committee成员。她有丰富的经验和对医疗保健深刻的了解。2005年她被授予终身贵族并成为下院议员(1984年到2005年)。她相继地担任卫生大臣和民族遗产秘书。她担任许多公共和私人医疗保健部门的职务。
Baroness Bottomley gained her MSc in Social Administration from the London School of Economics following her first degree. She was appointed a Life Peer in 2005 following her career as a Member of Parliament between 1984 and 2005. She served successively as Secretary of State for Health and then Culture, Media and Sport. Virginia was formerly a director of Bupa and AkzoNobel NV. She is currently a director of International Resources Group Limited, member of the International Advisory Council of Chugai Pharmaceutical Co, Chancellor of University of Hull and Sheriff of Hull and Trustee of The Economist Newspaper. She is the Chair of Board & CEO Practice at Odgers Berndtson.

高管简历

中英对照 |  中文 |  英文
Graham Baker

Graham Baker持有剑桥大学经济学硕士学位,并有资格成为安达信会计师事务所的特许会计师和特许税务顾问。1995年,他加入AstraZeneca PLC,在那里工作了20年,担任多个高级职位,包括Vice President、财务、国际(2013年至2015年),负责所有新兴市场、Vice President、全球金融服务(2011年至2013年)和北美Vice President财务和首席财务官(2008年至2010年)。最近,格雷厄姆是仿制药公司Alvogen的首席财务官。


Graham Baker holds an MA degree in Economics from Cambridge University and qualified as a Chartered Accountant and Chartered Tax Advisor with Arthur Andersen. In 1995, he joined AstraZeneca PLC where he worked for 20 years, holding multiple senior roles, including Vice President, Finance, International (2013-2015) with responsibility for all emerging markets, Vice President, Global Financial Services (2011-2013) and Vice President Finance & Chief Financial Officer, North America (2008-10). Most recently, Graham was Chief Financial Officer of generic pharmaceuticals company Alvogen.
Graham Baker持有剑桥大学经济学硕士学位,并有资格成为安达信会计师事务所的特许会计师和特许税务顾问。1995年,他加入AstraZeneca PLC,在那里工作了20年,担任多个高级职位,包括Vice President、财务、国际(2013年至2015年),负责所有新兴市场、Vice President、全球金融服务(2011年至2013年)和北美Vice President财务和首席财务官(2008年至2010年)。最近,格雷厄姆是仿制药公司Alvogen的首席财务官。
Graham Baker holds an MA degree in Economics from Cambridge University and qualified as a Chartered Accountant and Chartered Tax Advisor with Arthur Andersen. In 1995, he joined AstraZeneca PLC where he worked for 20 years, holding multiple senior roles, including Vice President, Finance, International (2013-2015) with responsibility for all emerging markets, Vice President, Global Financial Services (2011-2013) and Vice President Finance & Chief Financial Officer, North America (2008-10). Most recently, Graham was Chief Financial Officer of generic pharmaceuticals company Alvogen.
Susan Swabey

Susan Swabey在2009年5月被任命为公司秘书。


Susan Swabey has 30 years’ experience as a Company Secretary in a wide range of companies including Prudential plc, Amersham plc and RMC Group plc. Her work has covered Board support, corporate governance, corporate transactions, Group risk management, share registration, listing obligations, corporate social responsibility, pensions, insurance and employee and executive share plans. Susan is joint Vice-Chair of the GC100 Group, a member of the CBI Companies Committee and is a frequent speaker on corporate governance and related matters. She is also a Trustee of ShareGift, the share donation charity.
Susan Swabey在2009年5月被任命为公司秘书。
Susan Swabey has 30 years’ experience as a Company Secretary in a wide range of companies including Prudential plc, Amersham plc and RMC Group plc. Her work has covered Board support, corporate governance, corporate transactions, Group risk management, share registration, listing obligations, corporate social responsibility, pensions, insurance and employee and executive share plans. Susan is joint Vice-Chair of the GC100 Group, a member of the CBI Companies Committee and is a frequent speaker on corporate governance and related matters. She is also a Trustee of ShareGift, the share donation charity.
Glenn Warner

Glenn Warner于2014年6月加入Smith & Nephew,负责先进伤口管理的全球特许经营战略,市场营销和生产发展,及其美国商业业务。


Glenn Warner joined Smith & Nephew in June 2014 with responsibility for Advanced Wound Management’s global franchise strategy, marketing and product development, as well as its US commercial business. With effect from 1 January 2016 Glenn became the President of Smith & Nephew’s US business responsible for all the US commercial business. He is based in Fort Worth.
Glenn Warner于2014年6月加入Smith & Nephew,负责先进伤口管理的全球特许经营战略,市场营销和生产发展,及其美国商业业务。
Glenn Warner joined Smith & Nephew in June 2014 with responsibility for Advanced Wound Management’s global franchise strategy, marketing and product development, as well as its US commercial business. With effect from 1 January 2016 Glenn became the President of Smith & Nephew’s US business responsible for all the US commercial business. He is based in Fort Worth.
Elga Lohler

Elga Lohler,2002年加入Smith & Nephew,2015年12月成为首席人力资源官。Elga领导全球人力资源、外部通讯和可持续性职能部门。她住在伦敦。


Elga Lohler joined Smith & Nephew in 2002 and became Chief Human Resources Officer in December 2015. Elga leads the Global Human Resources, Internal Communication and Sustainability Functions. She is based in London.
Elga Lohler,2002年加入Smith & Nephew,2015年12月成为首席人力资源官。Elga领导全球人力资源、外部通讯和可持续性职能部门。她住在伦敦。
Elga Lohler joined Smith & Nephew in 2002 and became Chief Human Resources Officer in December 2015. Elga leads the Global Human Resources, Internal Communication and Sustainability Functions. She is based in London.
Matthew Stober

Matthew Stober,2015年10月1日加入Smith & Nephew,负责全球制造、供应链、分销、质量保证、监督事务、直接采购和制造IT优化。他住在孟菲斯市。


Matthew Stober joined Smith & Nephew on 1 October 2015 with responsibility for global manufacturing, supply chain, distribution, quality assurance, regulatory affairs, direct procurement, and manufacturing IT optimisation. Initially based in Memphis, Matt is now based in Andover, Massachusetts.
Matthew Stober,2015年10月1日加入Smith & Nephew,负责全球制造、供应链、分销、质量保证、监督事务、直接采购和制造IT优化。他住在孟菲斯市。
Matthew Stober joined Smith & Nephew on 1 October 2015 with responsibility for global manufacturing, supply chain, distribution, quality assurance, regulatory affairs, direct procurement, and manufacturing IT optimisation. Initially based in Memphis, Matt is now based in Andover, Massachusetts.
Brad Cannon

Brad Cannon于2012年加入Smith&Nephew,并于2016年3月成为欧洲和加拿大总裁。他的总部设在瑞士巴尔。


Brad Cannon joined Smith & Nephew in 2012 and became President, Europe and Canada in March 2016. He is based in Baar, Switzerland.
Brad Cannon于2012年加入Smith&Nephew,并于2016年3月成为欧洲和加拿大总裁。他的总部设在瑞士巴尔。
Brad Cannon joined Smith & Nephew in 2012 and became President, Europe and Canada in March 2016. He is based in Baar, Switzerland.
Vasant Padmanabhan

Vasant Padmanabhan于2016年8月加入Smith&Nephew,负责研究和创新、新产品开发、安全事务、临床事务、医疗器械/药物警戒和临床运营。他的总部设在马萨诸塞州安多弗。


Vasant Padmanabhan joined Smith & Nephew in August 2016 and is responsible for Research and Innovation, New Product Development, Safety Affairs, Clinical Affairs, Medical Device/Pharmacovigilance and Clinical Operations. He is based in Andover, Massachusetts.
Vasant Padmanabhan于2016年8月加入Smith&Nephew,负责研究和创新、新产品开发、安全事务、临床事务、医疗器械/药物警戒和临床运营。他的总部设在马萨诸塞州安多弗。
Vasant Padmanabhan joined Smith & Nephew in August 2016 and is responsible for Research and Innovation, New Product Development, Safety Affairs, Clinical Affairs, Medical Device/Pharmacovigilance and Clinical Operations. He is based in Andover, Massachusetts.
Olivier Bohuon

Olivier Bohuon自2019年1月起担任武田的外部董事。在任命之前,Bohuon先生是Shire的外部董事。Bohuon先生目前还担任LEO Pharma A/S的外部董事和副董事长,以及史密斯集团的外部董事。Bohuon先生曾担任Virbac SA的外部董事、Smith&Nephew plc的首席执行官、Pierre Fabre Group SA的首席执行官兼总裁以及雅培制药的总裁;美国雅培实验室的一个分支。他还曾在葛兰素史克(GlaxoSmithKline)及其法国前身公司担任过多种商业领导职务。在加入Smith & Nephew之前,他是 Abbott Pharmaceuticals(美国雅培公司(Abbott Laboratories)的一个部门)的总裁负责整个业务包括研发、全球生产和全球支持。他持有巴黎高等商学院(HEC Paris School of Management)的工商管理硕士学位和巴黎大学(University of Paris)的药剂学博士学位。


Olivier Bohuon,has been an External Director with Takeda since January 2019. Prior to his appointment, Mr. Bohuon was an External Director of Shire. Mr. Bohuon currently also holds the position of External Director and Chairman at Majorelle International, External Director at Virbac SA, External Director at AlgoTherapeutix SAS and External Director at Reckitt Benckiser Group plc. Mr. Bohuon has previously served as External Director and Chairman at LEO Pharma A/S, Chief Executive Officer of Smith & Nephew plc, Chief Executive Officer and President of Pierre Fabre Group SA and as President of Abbott Pharmaceuticals; a division of US-based Abbott Laboratories. He has also held diverse commercial leadership positions at GlaxoSmithKline and its predecessor companies in France.
Olivier Bohuon自2019年1月起担任武田的外部董事。在任命之前,Bohuon先生是Shire的外部董事。Bohuon先生目前还担任LEO Pharma A/S的外部董事和副董事长,以及史密斯集团的外部董事。Bohuon先生曾担任Virbac SA的外部董事、Smith&Nephew plc的首席执行官、Pierre Fabre Group SA的首席执行官兼总裁以及雅培制药的总裁;美国雅培实验室的一个分支。他还曾在葛兰素史克(GlaxoSmithKline)及其法国前身公司担任过多种商业领导职务。在加入Smith & Nephew之前,他是 Abbott Pharmaceuticals(美国雅培公司(Abbott Laboratories)的一个部门)的总裁负责整个业务包括研发、全球生产和全球支持。他持有巴黎高等商学院(HEC Paris School of Management)的工商管理硕士学位和巴黎大学(University of Paris)的药剂学博士学位。
Olivier Bohuon,has been an External Director with Takeda since January 2019. Prior to his appointment, Mr. Bohuon was an External Director of Shire. Mr. Bohuon currently also holds the position of External Director and Chairman at Majorelle International, External Director at Virbac SA, External Director at AlgoTherapeutix SAS and External Director at Reckitt Benckiser Group plc. Mr. Bohuon has previously served as External Director and Chairman at LEO Pharma A/S, Chief Executive Officer of Smith & Nephew plc, Chief Executive Officer and President of Pierre Fabre Group SA and as President of Abbott Pharmaceuticals; a division of US-based Abbott Laboratories. He has also held diverse commercial leadership positions at GlaxoSmithKline and its predecessor companies in France.
Michael Frazzette

Michael Frazzette, 他是内窥镜检查总裁。2006年7月,他加入集团担任内窥镜检查总裁。此前,他曾担任一家美国医疗设备制造商的总裁和首席执行官,曾在泰科健康(Tyco Healthcare)工作15年,担任病人护理、THC加拿大和卫生系统部门总裁。


Michael Frazzette joined Smith & Nephew in July 2006 as President of the Endoscopy Global Business Unit. From 2011 to 2015 he headed up the Advanced Surgical Devices division with responsibility for the Orthopaedic Reconstruction, Trauma, Sports Medicin, GYN and ENT Global Franchises, as well as the ASD commercial business in the US. The scope of Mike’s role was expanded in 2014 to include the Latin American commercial business, together with Advanced Wound Management. Mike is based in London.
Michael Frazzette, 他是内窥镜检查总裁。2006年7月,他加入集团担任内窥镜检查总裁。此前,他曾担任一家美国医疗设备制造商的总裁和首席执行官,曾在泰科健康(Tyco Healthcare)工作15年,担任病人护理、THC加拿大和卫生系统部门总裁。
Michael Frazzette joined Smith & Nephew in July 2006 as President of the Endoscopy Global Business Unit. From 2011 to 2015 he headed up the Advanced Surgical Devices division with responsibility for the Orthopaedic Reconstruction, Trauma, Sports Medicin, GYN and ENT Global Franchises, as well as the ASD commercial business in the US. The scope of Mike’s role was expanded in 2014 to include the Latin American commercial business, together with Advanced Wound Management. Mike is based in London.
Jack Campo

Jack Campo,他是首席法务官。他于2008年6月加入Smith & Nephew并领导全球法律职能。他最初居住在伦敦。2011年底以来,他在马萨诸塞州安德沃居住。在加入 Smith & Nephew之前,他担任the General Electric Company的许多高级法律职务,包括7年美国和亚洲的GE Healthcare GE Medical Systems。他的事业始于Davis Polk & Wardwell。


Jack Campo joined Smith & Nephew in June 2008 and heads up the Global Legal function. Initially based in London, he has been based in Andover, Massachusetts since late 2011.
Jack Campo,他是首席法务官。他于2008年6月加入Smith & Nephew并领导全球法律职能。他最初居住在伦敦。2011年底以来,他在马萨诸塞州安德沃居住。在加入 Smith & Nephew之前,他担任the General Electric Company的许多高级法律职务,包括7年美国和亚洲的GE Healthcare GE Medical Systems。他的事业始于Davis Polk & Wardwell。
Jack Campo joined Smith & Nephew in June 2008 and heads up the Global Legal function. Initially based in London, he has been based in Andover, Massachusetts since late 2011.
Olivier Bohuon

Olivier Bohuon,他是首席执行官。2011年4月他被任命为首席执行官。他是提名和治理委员会成员。他有在许多制药和医疗保健公司提名和治理委员会任职的丰富经验。在加入Smith & Nephew之前,他是 Abbott Pharmaceuticals(美国雅培公司(Abbott Laboratories)的一个部门)的总裁负责整个业务包括研发、全球生产和全球支持。


Olivier Bohuon was appointed to the Board on July 1 2015 and is a member of the Remuneration Committee and the Nomination & Governance Committee. He is to be appointed Senior Independent Director with effect from the conclusion of the 2018 Annual General Meeting. Mr. Bohuon currently holds the positions of Chief Executive Officer at Smith & Nephew plc, Non-Executive Director at Biotech Promise and Non-Executive Director at Virbac SA, having previously served as Chief Executive Officer and President of Pierre Fabre Group and as President of Abbott Pharmaceuticals; a division of US-based Abbott Laboratories. He has also held diverse commercial leadership positions at GlaxoSmithKline and its predecessor companies in France. Mr. Bohuon holds an MBA from HEC Paris School of Management and a doctorate in Pharmacy from the University of Paris.
Olivier Bohuon,他是首席执行官。2011年4月他被任命为首席执行官。他是提名和治理委员会成员。他有在许多制药和医疗保健公司提名和治理委员会任职的丰富经验。在加入Smith & Nephew之前,他是 Abbott Pharmaceuticals(美国雅培公司(Abbott Laboratories)的一个部门)的总裁负责整个业务包括研发、全球生产和全球支持。
Olivier Bohuon was appointed to the Board on July 1 2015 and is a member of the Remuneration Committee and the Nomination & Governance Committee. He is to be appointed Senior Independent Director with effect from the conclusion of the 2018 Annual General Meeting. Mr. Bohuon currently holds the positions of Chief Executive Officer at Smith & Nephew plc, Non-Executive Director at Biotech Promise and Non-Executive Director at Virbac SA, having previously served as Chief Executive Officer and President of Pierre Fabre Group and as President of Abbott Pharmaceuticals; a division of US-based Abbott Laboratories. He has also held diverse commercial leadership positions at GlaxoSmithKline and its predecessor companies in France. Mr. Bohuon holds an MBA from HEC Paris School of Management and a doctorate in Pharmacy from the University of Paris.
Cyrille Petit

Cyrille Petit,他担任首席公司发展官。2012年5月他加入Smith & Nephew并领导公司发展职务。他居住在伦敦。在通用电气公司(General Electric Company)的前15年职业生涯,他担任先是通用金融(GE Capital),随后GE Healthcare的高级职务并不断被提拔。最后,他担任运输部的总经理负责全球业务拓展。他的事业始于BNP Paribas以及后来的高盛投资公司(Goldman Sachs),他负责投资银行业务。


Cyrille Petit joined Smith & Nephew in May 2012 and leads the Corporate Development function and from October 2015 the Global Business Services. He is based in London.
Cyrille Petit,他担任首席公司发展官。2012年5月他加入Smith & Nephew并领导公司发展职务。他居住在伦敦。在通用电气公司(General Electric Company)的前15年职业生涯,他担任先是通用金融(GE Capital),随后GE Healthcare的高级职务并不断被提拔。最后,他担任运输部的总经理负责全球业务拓展。他的事业始于BNP Paribas以及后来的高盛投资公司(Goldman Sachs),他负责投资银行业务。
Cyrille Petit joined Smith & Nephew in May 2012 and leads the Corporate Development function and from October 2015 the Global Business Services. He is based in London.
Rodrigo Bianchi

Rodrigo Bianchi,他是IRAMEA的总裁。他于2013年7月加入Smith & Nephew并负责继续我们在大中华、印度、俄罗斯、亚洲、中东和非洲的强劲势头。他在迪拜居住。他在医疗行业的经验包括在强生公司(Johnson & Johnson )担任26年高级职务并不断被提拔。在担任Mitek and Ethicon的总裁之前,他担任地中海地区的医疗设备和诊断部门区域副总裁。他的事业始于意大利的宝洁(Procter & Gamble)。


Rodrigo Bianchi joined Smith & Nephew in July 2013 with responsibility for Greater China, India, Russia, Asia, Middle East and Africa, focusing on continuing our strong momentum in these regions. He is based in Dubai. With effect from 1 January 2016 Rodrigo became responsible, not only for the IRAMEA markets, but Latin America, Australia, New Zealand and Japan as well.
Rodrigo Bianchi,他是IRAMEA的总裁。他于2013年7月加入Smith & Nephew并负责继续我们在大中华、印度、俄罗斯、亚洲、中东和非洲的强劲势头。他在迪拜居住。他在医疗行业的经验包括在强生公司(Johnson & Johnson )担任26年高级职务并不断被提拔。在担任Mitek and Ethicon的总裁之前,他担任地中海地区的医疗设备和诊断部门区域副总裁。他的事业始于意大利的宝洁(Procter & Gamble)。
Rodrigo Bianchi joined Smith & Nephew in July 2013 with responsibility for Greater China, India, Russia, Asia, Middle East and Africa, focusing on continuing our strong momentum in these regions. He is based in Dubai. With effect from 1 January 2016 Rodrigo became responsible, not only for the IRAMEA markets, but Latin America, Australia, New Zealand and Japan as well.